(Reuters) -UK’s Haleon reported annual profit in line with market expectations on Thursday, as the Sensodyne toothpaste and Advil painkiller maker was helped by sustained demand for its multi-vitamin and oral health products.
Strong demand for multi-vitamins and oral hygiene products due to a growing consumer focus on wellness are cushioning the impact of a stronger pound and a post-pandemic slowdown in cold and pain medicines’ demand on the British consumer healthcare firm.
The company, spun off from drugmaker GSK in 2022, reported revenue of 11.23 billion pounds ($14.21 billion) for the 12 months ended December 31, 2024, in line with analysts’ estimate of 11.22 billion pounds in a company-compiled consensus.
Adjusted operating profit stood at 2.50 billion pounds, also matching analysts’ expectation.
Haleon also said that it had allocated 500 million pounds for share buybacks in the current year, in which it also expects organic revenue to grow between 4% and 6%.
($1 = 0.7900 pounds)
(Reporting by Raechel Thankam Job and Pushkala Aripaka in Bengaluru; Editing by Rashmi Aich)
